Jefferies ups ALK-Abello on strong launch pipeline

Alk-Abello A/S

31/01/2025 09:18

** Jefferies ups rating on Danish allergy vaccines maker
ALK-Abello  ALKb.CO  to "buy" from "hold," citing upcoming
paediatric launches, peanut allergy tablet potential and growth
prospects for its needle-free adrenaline spray    
    ** "We become more positive on ALK's growth profile, with
recent weakness attractive ahead of multiple launches 2H25 and
peanut tablet update in 1H26," the brokerage says in a note
    ** It adds that channel checks suggest paediatric launches
are eagerly anticipated, while the needle-free adrenaline could
drive +5%-10% annual market volume growth
   ** Out of six analysts that cover ALK-Abello, five rate the
stock "strong buy" or "buy," and​ one analyst rates it "hold" 
    ** Shares in ALK-Abello rise 7.5% in morning trade and are
among top performers of the pan-European STOXX 600 index
 .STOXX 
    ** If gains hold, the shares are on track for their best day
since August 2024
    

 (Reporting by Jesus Calero)
 ((jesus.calero@thomsonreuters.com))